Cargando…

The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China

BACKGROUND: The novel coronavirus disease 2019 (COVID-19) broke out globally. Early prediction of the clinical progression was essential but still unclear. We aimed to evaluate the timeline of COVID-19 development and analyze risk factors of disease progression. METHODS: In this retrospective study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fang, Qu, Mengyuan, Zhou, Xuan, Zhao, Kai, Lai, Changxiang, Tang, Qiyuan, Xian, Wenjie, Chen, Ruikun, Li, Xuan, Li, Zhiyu, He, Qing, Liu, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332535/
https://www.ncbi.nlm.nih.gov/pubmed/32620125
http://dx.doi.org/10.1186/s12967-020-02423-8
_version_ 1783553546206052352
author Wang, Fang
Qu, Mengyuan
Zhou, Xuan
Zhao, Kai
Lai, Changxiang
Tang, Qiyuan
Xian, Wenjie
Chen, Ruikun
Li, Xuan
Li, Zhiyu
He, Qing
Liu, Lei
author_facet Wang, Fang
Qu, Mengyuan
Zhou, Xuan
Zhao, Kai
Lai, Changxiang
Tang, Qiyuan
Xian, Wenjie
Chen, Ruikun
Li, Xuan
Li, Zhiyu
He, Qing
Liu, Lei
author_sort Wang, Fang
collection PubMed
description BACKGROUND: The novel coronavirus disease 2019 (COVID-19) broke out globally. Early prediction of the clinical progression was essential but still unclear. We aimed to evaluate the timeline of COVID-19 development and analyze risk factors of disease progression. METHODS: In this retrospective study, we included 333 patients with laboratory-confirmed COVID-19 infection hospitalized in the Third People’s Hospital of Shenzhen from 10 January to 10 February 2020. Epidemiological feature, clinical records, laboratory and radiology manifestations were collected and analyzed. 323 patients with mild-moderate symptoms on admission were observed to determine whether they exacerbated to severe-critically ill conditions (progressive group) or not (stable group). We used logistic regression to identify the risk factors associated with clinical progression. RESULTS: Of all the 333 patients, 70 (21.0%) patients progressed into severe-critically ill conditions during hospitalization and assigned to the progressive group, 253 (76.0%) patients belonged to the stable group, another 10 patients were severe before admission. we found that the clinical features of aged over 40 (3.80 [1.72, 8.52]), males (2.21 [1.20, 4.07]), with comorbidities (1.78 [1.13, 2.81]) certain exposure history (0.38 [0.20, 0.71]), abnormal radiology manifestations (3.56 [1.13, 11.40]), low level of T lymphocytes (0.99 [0.997, 0.999]), high level of NLR (0.99 [0.97, 1.01]), IL-6 (1.05 [1.03, 1.07]) and CRP (1.67 [1.12, 2.47]) were the risk factors of disease progression by logistic regression. CONCLUSIONS: The potential risk factors of males, older age, with comorbidities, low T lymphocyte level and high level of NLR, CRP, IL-6 can help to predict clinical progression of COVID-19 at an early stage.
format Online
Article
Text
id pubmed-7332535
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73325352020-07-06 The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China Wang, Fang Qu, Mengyuan Zhou, Xuan Zhao, Kai Lai, Changxiang Tang, Qiyuan Xian, Wenjie Chen, Ruikun Li, Xuan Li, Zhiyu He, Qing Liu, Lei J Transl Med Research BACKGROUND: The novel coronavirus disease 2019 (COVID-19) broke out globally. Early prediction of the clinical progression was essential but still unclear. We aimed to evaluate the timeline of COVID-19 development and analyze risk factors of disease progression. METHODS: In this retrospective study, we included 333 patients with laboratory-confirmed COVID-19 infection hospitalized in the Third People’s Hospital of Shenzhen from 10 January to 10 February 2020. Epidemiological feature, clinical records, laboratory and radiology manifestations were collected and analyzed. 323 patients with mild-moderate symptoms on admission were observed to determine whether they exacerbated to severe-critically ill conditions (progressive group) or not (stable group). We used logistic regression to identify the risk factors associated with clinical progression. RESULTS: Of all the 333 patients, 70 (21.0%) patients progressed into severe-critically ill conditions during hospitalization and assigned to the progressive group, 253 (76.0%) patients belonged to the stable group, another 10 patients were severe before admission. we found that the clinical features of aged over 40 (3.80 [1.72, 8.52]), males (2.21 [1.20, 4.07]), with comorbidities (1.78 [1.13, 2.81]) certain exposure history (0.38 [0.20, 0.71]), abnormal radiology manifestations (3.56 [1.13, 11.40]), low level of T lymphocytes (0.99 [0.997, 0.999]), high level of NLR (0.99 [0.97, 1.01]), IL-6 (1.05 [1.03, 1.07]) and CRP (1.67 [1.12, 2.47]) were the risk factors of disease progression by logistic regression. CONCLUSIONS: The potential risk factors of males, older age, with comorbidities, low T lymphocyte level and high level of NLR, CRP, IL-6 can help to predict clinical progression of COVID-19 at an early stage. BioMed Central 2020-07-03 /pmc/articles/PMC7332535/ /pubmed/32620125 http://dx.doi.org/10.1186/s12967-020-02423-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Fang
Qu, Mengyuan
Zhou, Xuan
Zhao, Kai
Lai, Changxiang
Tang, Qiyuan
Xian, Wenjie
Chen, Ruikun
Li, Xuan
Li, Zhiyu
He, Qing
Liu, Lei
The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China
title The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China
title_full The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China
title_fullStr The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China
title_full_unstemmed The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China
title_short The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China
title_sort timeline and risk factors of clinical progression of covid-19 in shenzhen, china
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332535/
https://www.ncbi.nlm.nih.gov/pubmed/32620125
http://dx.doi.org/10.1186/s12967-020-02423-8
work_keys_str_mv AT wangfang thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT qumengyuan thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT zhouxuan thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT zhaokai thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT laichangxiang thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT tangqiyuan thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT xianwenjie thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT chenruikun thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT lixuan thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT lizhiyu thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT heqing thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT liulei thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT wangfang timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT qumengyuan timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT zhouxuan timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT zhaokai timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT laichangxiang timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT tangqiyuan timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT xianwenjie timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT chenruikun timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT lixuan timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT lizhiyu timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT heqing timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina
AT liulei timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina